This Evidence Watch reviews a 2026 systematic review on cannabinoids for autism in children and adolescents. The paper found limited RCT evidence, with one whole-plant high-CBD, low-THC extract showing improvement in global clinical impression and social responsiveness, while several other validated outcomes were null. The main caution is that pediatric ASD evidence remains heterogeneous, short-term, and not strong enough to support broad clinical recommendations